A 40-year-old male patient, with no cardiovascular risk factors or relevant clinical history, was referred to our institution for evaluation and treatment. He denied substance abuse or regular medication, and declared to be a high-performance athlete, trail runner of 70 km a week. At the end of a 27 km race, he presented an intense retrosternal oppressive pain, without irradiation, associated with dizziness, which disappeared at rest. It was initially interpreted as a muscular cramp and was treated with non-steroidal anti-inflammatory drugs in a local center. 48 hours later, he consulted a local hospital. There were no abnormal findings on first clinical examination. The 12-lead electrocardiogram (EKG) showed 60 bpm with negative T waves in DIII lead, and left ventricular hypertrophy (Figure 1 ). He presented a Troponin I value of 2.75 ng/ml (normal value: Less than 0.4 ng/ml), and Creatine Kinase of 475 U/ml (normal value: Less than 180 U/ml), rest of metabolic panel was within normal limits. An echocardiogram was performed which showed preserved left ventricular function with no alterations in segmental motility, without valvular disease; and a thoracic angiotomography that excluded aortic syndrome and pulmonary thromboembolism.
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In a second visit, a multislice computed coronary tomography (MSCT) was performed and revealed multiple
Introduction
Coronary fistulas (CF), initially described by Krause in 1865, are uncommon anomalies consistent in communication between coronary arteries and any cardiac cavity or vascular structure [1] .
The incidence of CF is 0.002% of general population, observed in 0.2% of adult patients undergoing coronary angiography [2] . More frequently of congenital origin, they have also been described related to invasive procedures, chest trauma or post myocardial infarction. In 55% of cases they are originated from the right coronary artery, in 35% from left coronary artery and 5% in both simultaneously. Seventy percent of CF drain into right cavities (low pressure circuits), 15% into pulmonary artery and just 3% into left cavities [2, 3] .
Most patients remain asymptomatic, and the onset of symptoms appearance depends on left-to-right shunt magnitude. In the long term and with diagnosis delay, CF may evolve to myocardial ischemia due to coronary steal, pulmonary hypertension, heart failure and ruptured fistula aneurysm. Therefore, its detection and early treatment in symptomatic patients is essential [3] .
We present a case of CF draining in a pulmonary artery with associated myocardial ischemia, with complex intravascular resolution.
From a multidisciplinary approach, given its clinical presentation and morphology of the fistulas, percutaneous treatment was decided. Fistulous tracts were cannulated selectively with Progreat® microcatheter mounted on a BMW 0.014 guide wire and Barricade® coils (Helical SR and Complex SR) were deployed (Figures 4A, Figure 4B , Figure 5A and Figure 5B ), with trivial residual flow. There were no complications during the procedure.
Two months after percutaneous treatment, a follow-up echocardiogram showed a high velocity flow along the origin of the RCA and continuous flow at pulmonary artery level; with a functional test without inpulmonary CF from the septal branch of the left anterior descending artery (LADA) and right coronary artery (RCA) (Figure 2 ). Suspecting associated myocardial infarction, a cardiac magnetic resonance was requested and showed late gadolinium enhancement in inferoapical segments, with necrotic ischemic pattern and transmural extension (Figure 3) . For treatment planning a coronary angiography was performed to evaluate CF morphology, observing a Sakakibara A complex and tortuous macrofistula emerging from the proximal segment of LADA with a common stem and 2 branches of 2 mm diameter each one, and a Sakakibara A macrofistula of 2mm diameter from the proximal segment of RCA, both draining into the pulmonary artery. within 85% of target heart rate, with periodical follow up with echocardiogram and Holter EKG. Competitive sport was discouraged. We support the idea to perform a new coronary angiogram in the near future, which is the best method to define CF anatomy and the amount of residual flow.
Discussion
Pulmonary CF present an uncertain evolution in adult patients, symptoms onset depends on time and fistula size. Angelini, et al. proposed a diagnostic algorithm, in which transthoracic echocardiography and stress duced ischemia and Holter EKG without ventricular arrhythmias. In addition, a MSCT revealed contrast opacification of pulmonary CF embolized with coils, not being able to specify if they were filled from the coronary or the pulmonary artery. Residual permeability of LADA coronary fistula was suspected, but the patient declined a confirmatory coronary angiography.
At discharge, he was treated with clopidogrel 75 mg and acetylsalicylic acid 100 mg. At 12 months he remains asymptomatic, and clopidogrel was stopped due to lack of evidence in long term benefits with this drug. He is performing low impact physical activity 
Conclusion
Pulmonary CF are rare anomalies with a broad clinical spectrum. The initial approach in adults is antiagregation and ruling out coronary ischemia. Any complication or symptom justifies aggressive treatment. The traditional one has been surgical, but in the last decades percutaneous treatment constitutes a valid option. The objective is to reduce ischemic risk, arrhythmias and fatal events. However, we recommend individual assessment of each patient to define treatment. This group requires periodic cardiological monitoring to detect new complications in the evolution.
Patient provided his informed consent for the publication of this case report.
tests play a major role in its detection. However, in patients with severe symptoms and suggestive physical examination and anamnesis, it is recommended to perform coronary angiography as gold standard [4] .
Definite closure is indicated in patients with large or complex CF regardless of symptoms. In those with moderate size, treatment should be performed if associated with symptoms, myocardial ischemia, arrhythmias, left ventricular dysfunction or endarteritis [5] .
Surgical ligature of CF was initially described by Biorck in 1947, and represents the most effective treatment [6] . Subsequently, percutaneous closure was developed using devices, reducing complications related to conventional surgery, with success rates of 86-90% in several series [7, 8] . It is indicated in CF with favorable anatomy (non-tortuous vessels, accessible distal portion and without other associated heart diseases). In complex and proximal fistulas, size is not the most relevant criteria for treatment [9] . Comparing observational cohorts of both techniques, percutaneous closure presents similar success rates and residual fistula (20-30%) compared to surgical approach [10] .
With proper treatment evolution is favorable, although long-term cardiological follow up is recommended to detect recanalization of fistulas, calcification, residual leaks and associated arrhythmias [5, 11] . According to clinical practice guidelines, it is possible to perform competitive physical activity after treatment in the absence of residual myocardial ischemia and ventricular arrhythmias in stress tests [12] .
There is no strong evidence supporting antiagregation after invasive treatment, anticoagulation is suggested in fistulas with aneurysms, associated thrombosis or residual slow flow [10] . 
